Skip to main content
Print Save

Retevmo FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 27, 2021.

FDA Approved: Yes (First approved May 8, 2020)
Brand name: Retevmo
Generic name: selpercatinib
Dosage form: Capsules
Company: Eli Lilly and Company
Treatment for: Non-Small Cell Lung Cancer, Thyroid Cancer

Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.

Development Timeline for Retevmo

DateArticle
May  8, 2020Approval  FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers
Jan 29, 2020Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Dec 30, 2019Lilly Opens Phase 3 Clinical Trial for Selpercatinib (LOXO-292) in RET-Mutant Medullary Thyroid Cancer
Sep 29, 2019Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers
Sep  9, 2019Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Oct 15, 2018Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer

See Also

Retevmo (selpercatinib) Consumer Information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer